Search Results - "Mudu, C"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia by Macciò, Antonio, Madeddu, Clelia, Massa, Daniela, Mudu, Maria C., Lusso, Maria R., Gramignano, Giulia, Serpe, Roberto, Melis, Gian Benedetto, Mantovani, Giovanni

    Published in Blood (01-07-2005)
    “…Anemia occurs in more than 30% of patients with epithelial ovarian cancer before any surgery. High levels of proinflammatory cytokines and increased oxidative…”
    Get full text
    Journal Article
  2. 2

    Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation by Mantovani, G, Maccio, A, Massa, E, Mulas, C, Mudu, M C, Massidda, S, Massa, D, Murgia, V, Ferreli, L, Succu, G, Astara, G, Proto, E, Tore, G, Mura, M, Maxia, G

    Published in International journal of oncology (01-06-2000)
    “…The purpose of the study was to assess response rate, clinical outcome, organ/function preservation and toxicity in head and neck cancer patients treated with…”
    Get more information
    Journal Article
  3. 3

    Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients by Mantovani, G, Ghiani, M, Curreli, L, Maccio, A, Massa, D, Succu, G, Lai, P, Massa, E, Mudu, M C, Astara, G

    Published in Oncology reports (01-03-1999)
    “…Despite the numerous studies demonstrating the effectiveness of epoetin á (human recombinant erythropoietin) versus placebo in cisplatin-induced anemia of…”
    Get more information
    Journal Article
  4. 4

    Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical response and organ/function preservation by Mantovani, G, Macciò, A, Massa, E, Mulas, C, Mudu, M C, Massidda, S, Massa, D, Murgia, V, Ferreli, L, Succu, G, Astara, G, Proto, E, Tore, G, Mura, M, Maxia, G

    Published in Oncology reports (01-11-1999)
    “…We planned to conduct a trial of induction chemotherapy followed by concomitant chemoradiotherapy with the goal of organ-function preservation in advanced head…”
    Get more information
    Journal Article
  5. 5
  6. 6

    Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha‐lipoic acid and N‐acetyl cysteine by Mantovani, Giovanni, Macciò, Antonio, Melis, Gianbenedetto, Mura, Loredana, Massa, Elena, Mudu, Maria Caterina

    Published in International journal of cancer (15-06-2000)
    “…The ability of Alpha‐Lipoic Acid (ALA) and N‐Acetyl Cysteine (NAC), two active antioxidant agents, to correct in vitro the most significant functional defects…”
    Get full text
    Journal Article
  7. 7

    Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy by Mantovani, G, Maccio, A, Madeddu, C, Massa, E, Mudu, M C, Mulas, C, Gramignano, G, Massidda, S, Murgia, V, Lusso, M R, Mura, L

    Published in International journal of oncology (01-02-2001)
    “…An open, non-randomized phase II study was carried out including all patients treated with whatever chemotherapy or combined modality regimen for whatever…”
    Get more information
    Journal Article
  8. 8

    Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites by MANTOVANI, Giovanni, MACCIO, Antonio, MURA, Loredana, MASSA, Elena, MUDU, Maria Caterina, MULAS, Carlo, LUSSO, Maria Rita, MADEDDU, Clelia, DESSI, Annita

    “…Leptin is a recently identified hormone produced by the adipocyte ob gene which acts as a negative feedback signal critical to the normal control of food…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Relationships betxween Fas expression, activation molecule CD25, and functional activity of tumor-associated lymphomonocytes from neoplastic effusions by Mantovani, G, Macciò, A, Massa, E, Lai, P, Manca, G, Mudu, C, Versace, R, Pusceddu, G

    Published in Oncology reports (01-01-1999)
    “…Fas ligand (FasL), a cell surface molecule belonging to the tumor necrosis factor family, binds to its receptor Fas, thus inducing apoptosis of Fas bearing…”
    Get more information
    Journal Article
  11. 11
  12. 12
  13. 13
  14. 14